《大行報告》星展升友邦(01299.HK)目標價至92元 料將迎來新一輪業務擴展周期
星展近日發表報告表示,友邦保險(01299.HK)旗下友邦中國於今年上半年貢獻總體新業務價佔比達38%,首次超出友邦香港的貢獻,隨著中國內地未來持續開放保險業市場,認為公司處有利位置,能捕捉相關增長,料友邦中國至2026年新業務價值可額外增加26億人民幣,估計將迎來新一輪擴展業務周期。
該行表示,重申對友邦保險「買入」投資評級,上調對其目標價由90元升至92元,此基於兩階段的內含價值增長模型預測,並對其估值預測延伸至2021財年。
星展稱,調低對友邦今明兩年新業價值預測均15%,以反映新冠疫情的影響,但同時上調對友邦中國新業務價值增長預測6至8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.